Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH
Mandate

Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH

November 30, 2018 M&A

Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.

The acquisition strengthens CELLINK’s offering of complete 3D bioprint solutions. The purchase price amounts to MEUR 5 as well as the assumption of net debt in a maximum amount of MEUR 0.4. The purchase price is paid with MEUR 2 in cash and MEUR 3 with CELLINK class B shares (issue in kind to be resolved by CELLINK’s extraordinary general meeting during December 2018).

Vinge’s team primarily consisted of responsible partner Anders Strid, Daniel Lennartsson (M&A) and Alexander Lindeberg (IP). Noerr through, among others, responsible partner Dr. Holger Alfes, acted as local counsel in Germany.
 

Related

Vinge has advised Boliden in connection with a directed share issue of SEK 3.75 billion

 Vinge has advised Boliden AB in connection with a directed share issue through which the company raises proceeds of approximately SEK 3.75 billion before transaction costs.
March 21, 2025

Vinge advises EQT on its EUR 890 million sale of Dellner Couplers to Wabtec

 Vinge together with Milbank advises the EQT VIII fund (“EQT”) on its sale of Dellner Couplers (“Dellner”), a leading provider of train connection systems for passenger rail, to Wabtec Corporation (a fortune 500 company listed on the New York Stock Exchange, NYSE: WAB). The transaction values Dellner at approximately EUR 890 million. The transaction is subject to customary conditions and regulatory approvals.
March 19, 2025

Vinge advises Ambea on the acquisition of Validia

 Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025